Our strategic focus on heart failure
Heart failure, a global health burden
We are investing in research for the future of the estimated 38 million people impacted by heart failure worldwide.
Heart failure is among the leading causes of death due to cardiovascular disease (CVD), and occurs when the heart is weakened and cannot pump enough blood to meet the body’s needs.
People with HF are likely to be diagnosed with significant cardiovascular (CV), renal and metabolic risk factors such as type-2 diabetes and chronic kidney disease (CKD). People with type-2 diabetes have 2-3 times greater risk of HF and are at an increased risk of having a heart attack or stroke than the population without type-2 diabetes, and approximately 50% of deaths in people with type-2 diabetes are caused by CVD.
Due to the interconnectivity of CV, renal and metabolic diseases, we are committed to taking an overarching cardio-renal-metabolic approach to researching and innovating medicines for patients with HF.
CVD-REAL: Large-scale real-world evidence data
AstraZeneca is investigating the potential impact of SGLT-2 inhibitors on hospitalisation for HF and death in patients with type-2 diabetes
CVD-REAL is the first large, multi-national real-world evidence study of its kind evaluating the risk of hospitalisation for HF and death from any cause in patients with type-2 diabetes receiving treatment with SGLT-2 inhibitors.
What we're working on
We’re dedicated to investigating the science behind HF and how we can find benefits across the cardio-renal-metabolic disease area.
MEDI6012 is a recombinant human enzyme that is designed to enhance reverse cholesterol transport and increase functional high-density lipoprotein. It is currently being evaluated in a number of cardiovascular conditions that we hope will help prevent heart failure.
A major milestone supporting our ambition in the area of HF is the progression of AZD8601, a modified VEGF-A mRNA developed in collaboration with Moderna Therapeutics. We hope that VEGF-A could one day provide a regenerative treatment option for patients with HF, diabetic wound healing and other ischaemic vascular diseases.
We jointly created the Integrated Cardio Metabolic Centre with Karolinska Institute, one of the world’s leading medical research universities. The Centre aims to identify and validate novel cardio-metabolic targets, focusing on three strategic research areas: HF, diabetes and CKD across small molecules and biologics. Through our alliance with Karolinska Institutet and Moderna Therapeutics, we are investigating a medicine aimed at treating HF and other microvascular diseases.
We know the heart has the potential to heal itself, the question is how? By working together towards a shared goal, these scientists think they might have found the answer.
Be among our employees who continue to make us an innovation-driven company that stands firmly among the world’s leaders in biopharmaceuticals.
1. Braunwald E. The war against heart failure: the Lancet lecture. Lancet. 2015; 385 (9970): 812-824.
2. Kumarswamy R, Thum T. Non-coding RNAs in Cardiac Remodeling and Heart Failure. Circulation Research. 2013; 113:676-689.
3. American Heart Association. What is Heart Failure? http://www.heart.org/HEARTORG/Conditions/HeartFailure/AboutHeartFailure/What-is-Heart-Failure_UCM_002044_Article.jsp#.WZOU-FF97IU. Accessed 15 August 2017.
4. Nwaneri C, Cooper H, Bowen-Jones D. Mortality in type 2 diabetes mellitus: magnitude of the evidence from a systematic review and metaanalysis. The British Journal of Diabetes & Vascular Disease. 2013;13(4):192-207.
5. Morrish NJ, et al. Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia. 2001;44 Suppl 2:S14-21.
6. Martín-Timón I, Sevillano-Collantes C, et al. Type 2 diabetes and cardiovascular disease: Have all risk factors the same strength? World J Diabetes. 2014;5(4):444-470.